Application of a first-pass effect model to characterize the pharmacokinetic disposition of venlafaxine after oral administration to human subjects

Drug Metabolism and Disposition

Volumn 25, Issue 10, 1997, Pages 1215-1218

  Taft, David R ^b   Iyer, Ganesh R ^b   Behar, Leon ^b   Digregorio, Robert V ^a  

^a LONG ISLAND UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; VENLAFAXINE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FIRST PASS EFFECT; HUMAN; MALE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOHEXANOLS; HUMANS; MALE; METABOLIC CLEARANCE RATE; SEROTONIN UPTAKE INHIBITORS;

EID: 0030862078     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. M. Gibaldi and S. Feldman: Pharmaeokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J. Pharm. Sci. 58, 1477-1480 (1969).
2. W. A. Colburn and M. Gibaldi: Pharmacokinetic model of presystemic metabolism. Drug Metab. Dispos. 6, 193-196 (1978).
3. M. Rowland: Influence of roule of administration on drug availability. J. Pharm. Sci. 61, 70-74 (1972).
4. M. Rowland, L. Z. Benet, and G. G. Graham: Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1, 123-136 (1973).
5. G. R. Wilkinson and D. G. Shand: A physiologic approach to hepatic drug clearance. Clin. Pharmacl. Ther. 18, 377-390 (1975).
6. K. S. Pang and M. Rowland: Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5, 625-653 (1977).
7. J. P. Feighner: The role of venlafaxine in antidepressant therapy. J. Clin. Psychiatry 55 (Suppl. A). 62-68 (1994).
8. Y. Lecrubier: Clinical utility of venlafaxine in comparison with other antide- pressants. Int. Clin. Psychopharmacol 10 (Suppl. 2). 29-35 (1995).
9. F. A. Muth, J. A. Moyer, J. T. Haskins, T. H. Andree, and G. E. M. Husbands: Biochemical, neurophysiological and behavioral effects of WY 45,233. it's enantiomers. and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23, 191-199 (1991).
10. D. R. Hicks, D. Wolaniuk, A. Russell, N. Cavanaugh, and M. Kraml: A high-performance liquid Chromatographie method for the simultaneous determination of venlafaxine and o-desmelhylvenlafaxine in biological fluids. Ther. Drug Monit. 16, 100-107 (1994).
11. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 28, 349-359 (1993).
12. S. V. Otton, S. E. Ball, S. W. Cheung, T. Inaba, R. L. Rudolph, and E. M. Sellers: Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br. J. Clin, Pharmacol. 41, 149-156 (1996).
13. M. Gibaldi and D. Perrier: "Phannacokinetics." Marcel Dekker, New York. 1982.
14. V. Parker, L. Pruitt, and K. Maloney: Effect of age and sex on the pharmacokinetics of venlafaxine. J. Clin. Pharmacol. 30, 832 (1990).
15. K.J. Klamerulus, K. Maloney, R. L. Rudolph, S. F. Siscnwine, W. J. Jusko, and S. T. Chiang: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol. 32, 716-724 (1992).
16. K. S. Pang and J. R. Gillette: A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and hepatic blood flow. J. Pharmacokinet. Biopharm. 6, 355-366 (1978).
17. J. G. Wagner: "Pharmacokinetics for the Pharmaceutical Scientist." Technonnc. Lancaster, PA. 1995.
18. S. M. Pond and T. N. Tozer: First-pass elimination: basic concepts and clinical consequences. Clin. Pharmacokinet. 9, 1-25 (1984).
19. K. F. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Kunze, J. D. Perkins, and J. R. Wilkinson: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996).